## FDA Demands More Liver Safety Data from Eli Lilly on Newly Approved Obesity Pill
The U.S. Food and Drug Administration has formally requested additional safety data from Eli Lilly concerning potential liver injury linked to its recently approved obesity pill. This regulatory scrutiny, detailed in an April 1 letter posted on the agency's website, signals ongoing safety concerns that could impact the drug's market position and prescribing patterns. The move comes as the pharmaceutical giant seeks to capitalize on the lucrative weight-loss market, now facing heightened post-approval oversight.

The FDA's letter specifically mandates that Eli Lilly conduct new post-marketing trials to assess risks related to cardiovascular events and delayed gastric emptying. Furthermore, the agency requires the drugmaker to perform a dedicated lactation study involving lactating women. These requirements go beyond standard approval conditions, indicating the FDA is taking a cautious, data-intensive approach to monitoring the long-term profile of this new therapeutic.

This development places significant operational and reputational pressure on Eli Lilly. Complying with these extensive post-marketing study demands will require substantial resources and could influence physician confidence in the drug. The FDA's focus on liver safety, in particular, introduces a key variable for market adoption and could shape the competitive landscape against other GLP-1 agonists and obesity treatments. For investors and healthcare providers, the agency's actions underscore that regulatory hurdles for blockbuster drugs extend well beyond initial approval.
---
- **Source**: STAT News
- **Sector**: The Lab
- **Tags**: FDA, Pharmaceuticals, Drug Safety, Obesity, Regulation
- **Credibility**: unverified
- **Published**: 2026-04-16 00:22:34
- **ID**: 66463
- **URL**: https://whisperx.ai/en/intel/66463